Keyphrases
Niemann-Pick C1-like 1 (NPC1L1)
100%
NP-C
100%
Disease Biomarker
100%
Sphingolipid Profiling
100%
Sphingolipids
42%
Sphingoid Bases
42%
Hexosylceramide
42%
Disease Progression
28%
Cerebrospinal Fluid
28%
Clinical Trials
28%
Hydroxypropyl-β-cyclodextrin (HP-β-CD)
28%
GM2 Ganglioside
28%
Ganglioside GM3
28%
Miglustat
28%
Treatment Options
14%
Liver
14%
Effective Treatment
14%
Lipids
14%
Neurodegenerative Diseases
14%
Human Subjects
14%
Ceramide
14%
Therapy Efficacy
14%
Niemann-Pick Type C
14%
Response to Treatment
14%
Mouse Tissue
14%
GM1 Ganglioside
14%
Feline Model
14%
Complex Lipids
14%
Lipid Biomarkers
14%
Targeted Proteomics
14%
Lipid Storage
14%
Model Following
14%
Monitoring Efficacy
14%
Barriers to Growth
14%
Plasma Reduction
14%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Sphingolipid
100%
Diseases
100%
Clinical Trial
50%
Disease Exacerbation
50%
Miglustat
50%
Ganglioside GM3
50%
Ganglioside GM2
50%
Cyclodextrin
50%
Ceramide
25%
Feline Model
25%
Degenerative Disease
25%
Ganglioside GM1
25%
Homo sapiens
25%
Biochemistry, Genetics and Molecular Biology
NPC1
100%
Sphingolipid
100%
Blood Plasma
50%
Clinical Trial
33%
Lipid
33%
GM3
33%
Miglustat
33%
Cyclodextrin
33%
Ganglioside
33%
Animal Model
16%
Lipid Storage
16%
Metabolomics
16%
Feline Model
16%
GM1
16%
GM2 (Ganglioside)
16%
Ceramide
16%
Homo sapiens
16%